• New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior
• End-to-end support from experimental design to data interpretation

These capabilities have been developed to enhance Absorption, Distribution, Metabolism and Excretion (ADME) profiling, for accelerated drug discovery and development workflows.

This launch represents the Company’s new in silico tools available to customers and is designed to enhance data generation from its range of predictive in vitro tools – unlocking deeper insights into key ADME parameters, including human bioavailability, and enabling more confident in vitro to in vivo extrapolation (IVIVE).

CN Bio’s computational tools combine the insights gained from microphysiological system (MPS) assays with powerful mathematical models. These tools complement the Company’s existing bioavailability assay based on its proprietary dual-organ Gut/Liver model, available via the CRS or as an off-the-shelf kit. The derived data is fully compatible with physiologically-based pharmacokinetic (PBPK) frameworks and can be used to extract additional data from preclinical studies, providing functional predictions of how compounds interact with human biology.

By working with CN Bio’s CRS team, customers gain access to broad support and expertise from both MPS and computational modelling specialists. The team collaborates closely with customers throughout the process, from ensuring robust study design to translating experimental data into meaningful ADME predictions. Raw data generated from projects is also translated into an easy-to-interpret format, suitable for supporting go/no go and drug dosing decisions.

Dr Yassen Abbas, Lead Scientist, CN Bio, said:

“This year, the FDA made significant changes to phase out animal testing requirements, signalling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing. We are providing the tools to ensure our customers stay ahead of these regulatory changes.” He added: “The launch of our Bioavailability assay last year was a major step towards improving understanding of the appropriate dose regimens for safe and effective new therapies. Now, by integrating advanced in silico modelling into our offering, we are enhancing this service to bridge the in vitro to in vivo translation gap for drug developers. By working with our expert CRS team, customers have access to dedicated support throughout the entire process.”

For more information on CN Bio’s ADME CRS portfolio, visit…

Dr. Kleinstreuer emphasized that this shift reflects not only scientific advancement but a strategic and ethical imperative to modernize biomedical research. “True impact really requires a workforce trained in modern methods and data-driven decision-making to ensure that the most effective tools are prioritized,” she said. 

The NIH aims to establish a dedicated Office of Research Innovation, Validation, and Application (ORIVA) to support the integration of New Approach Methodologies (NAMs). This move builds on existing NIH efforts to scale technologies such as organoids, 3D bioprinting, AI-driven modeling, and microphysiological systems. 

“It’s not about shutting down animal labs overnight,” Dr. Kleinstreuer explained. “We’re creating the policy, infrastructure, and partnerships that make sustainable adoption possible.” 

NIH’s commitment marks a significant cultural and scientific shift toward more predictive, reproducible, and human-relevant research approaches—with the goal of transforming biomedical research from the ground up. 

This sentiment reflects the NIH’s formal press release on April 29th, citing their plans to reduce animal use in NIH-funded research, which landed just days after the FDA’s announcement on April 10th, citing their commitment to reduce animal testing in drug development.

“Ushering in a new era of innovation”, the NIH’s press release acknowledges that human-based research technologies “offer unique strengths that, when used correctly or in combination (with animals), can expand the toolbox for researchers to answer previously difficult or unanswerable biomedical research questions.”

The NIH plans to establish the Office of Research Innovation, Validation, and Application (ORIVA) to:

Coordinate efforts to develop, validate, and scale non-animal approaches across the agency
Serve as a hub for interagency coordination and regulatory translation for public health protection.
Expand funding and training in non-animal approaches and awareness of their value in translational success.
Expand infrastructure to make non-animal approaches more accessible to researchers.
Publicly report on research spending to measure progress toward reduced funding for animal studies and increased funding for human-based approaches.

View the full press release here: NIH to prioritize human-based research technologies | National Institutes of Health (NIH)

At CN Bio, we’ve spent over a decade developing and optimizing our PhysioMimix® OOC Systems and solutions, to better mimic human biology in the lab. These recent announcements affirm a transformative shift toward tools, such as OOC, which enable better predictivity and clinical translatability.

At the intersection of innovation, collaboration, and science lies an exciting new project led by the 3Rs Collaborative (3RsC) – and CN Bio is one of the collaborators. This effort brings together regulators, technology providers, end-users, and non-profits to advance the responsible use of microphysiological systems (MPS) in regulatory applications. 

In partnership with 3RsC, the FDA Center for Drug Evaluation and Research (CDER), 9 commercial providers, 1 end-user, NIH-NICEATM, and C-Path, we are embarking on a project to evaluate the use of Liver MPS to detect Drug-induced liver injury (DILI). Our goal is to assess variability across multiple platforms using the same experimental protocol, with the ultimate goal of enhancing confidence in the accuracy, reliability, and standardized characterization of these models. 

  Why this matters

This is more than a study. It’s a model for how different stakeholders such as regulators, developers, NIH and pharma end-users, can shape the future of drug development through the use of novel alternative methods. Our approach in this collaboration is focused on obtaining information that is human-relevant, data-rich, and aligned with the 3Rs. 

  What we’re doing

• Testing known hepatotoxicants & their controls across 9 unique, commercially available liver MPS platforms 
• Using real-world protocols to reflect what regulators might see in real submissions 
• Analyzing cross-platform data to inform best practices and future guidance 
• Submitting a collaborative letter of intent to FDA’s Innovative Science & Technology Approaches for New Drugs (ISTAND) program to qualify MPS for a specific context of use 

This is a first-of-its-kind, coordinated effort to harmonize innovation, good science while keeping regulatory considerations in mind—and it’s just the beginning. 

The future of science is collaborative

It highlights scientific rigor, innovation, and ethical considerations. And it’s already underway. 

Participating end-user:

Merck & Co, Inc. 

Participating model developers:

Axiom/LifeNet Health, BioIVT, CN Bio, DefiniGEN, InSphero, Lena Biosciences, Inc., PredictCan, TissUse, Xellar. 

Click the links to find out more about our Liver MPS (also known as Liver-on-a-chip), DILI assays powered by PhysioMimix technology and our cross-species DILI Contract Research Services.

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS).

Building upon the Company’s FDA-recognized drug induced liver injury (DILI) assay, the expanded offering enables rapid, comparative studies between commonly used animal and human models to flag interspecies differences early, and better informs in vivo study design.

Traditional human in vitro methods have limited capacity to accurately determine drug toxicity. Added to this, the discrepancies between these methods and in vivo animal studies make it challenging to accurately predict safety risks for humans during preclinical testing. Often, unsafe drug candidates are wrongly progressed, and potentially life-saving ones are misclassified and abandoned, ultimately impacting clinical progression. In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix^® DILI assay, adding the ability to easily compare results across human-, rat-, and dog-derived Liver-on-a-chip models. These assays offer a modernized workflow to generate predictive and actionable insights that mitigate the risk of costly, late-stage conflicting data, and reduce unnecessary animal use by providing early warning of hepatotoxicity/DILI prior to in vivo studies.

Accessible through the Company’s CRS, the new offering harnesses the longstanding expertise of CN Bio’s scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions beyond what is achievable using existing in vitro models. The assay enables a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression.

Dr Emily Richardson, Lead Scientist, Safety and Toxicology, CN Bio, said: “Understanding safety risks is critical to successful drug development, however, fundamental physiological and biological differences between species can lead to inaccuracies in predictions, often causing drug candidates to be wrongfully abandoned as toxic, or worse, mistakenly classified as safe.” She added: “Having established our DILI assay as an industry leading option to garner more valuable insights across the development pipeline, we were in an ideal position to expand its capabilities and address this crucial gap in understanding hepatotoxicity using the most commonly used animal models. Partnering with us to utilize this powerful service not only ensures robust and reliable results but also provides access to a team of Organ-on-a-chip experts, who are invested in your success; to de-risk your pipeline and move it forward with confidence.”

Learn more about our cross-species DILI services

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea. The agreement is the latest milestone in CN Bio’s international expansion, amplifying the Company’s presence in major Asian and Pacific markets and broadening access to its predictive human organ models.

Pharmaceutical and biotech companies are recognizing the potential of non-animal, new approach methodologies (NAMs) to improve preclinical efficacy and safety data generation in drug discovery and development workflows, leading to reduced failure rates of new drug candidates. In this pioneering field, the market is rapidly evolving in line with breaking regulatory developments, most recently the FDA announcing a shift toward human-relevant methods for drug development, replacing animal testing in the evaluation of monoclonal antibody therapies and other drugs¹.

Central to the Company’s ongoing growth strategy, CN Bio is establishing regional supply networks through specialist distribution partners to address growing demand for its FDA-recognized PhysioMimix^® OOC System and solutions. With the surge in South Korea’s biotech sector, driven by a series of billion-dollar licensing deals in early 2025 and the announcement of a new fund to support high-tech industries, the agreement with SCINCO uniquely positions CN Bio to support and expand operations in this high growth market. The partnership complements the Company’s wider network in the APAC region, including recently appointed Japanese distributor, Primetech².

CN Bio’s industry-leading benchtop PhysioMimix OOC range accurately mimics human physiology in the lab. Using advanced in vitro human organ models, these systems enable more accurate predictions of human drug responses to support the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal studies. These models provide insights into crucial aspects of preclinical drug development, including drug bioavailability, toxicology and disease modelling, providing information on how drugs will perform in patients and reduce the risk of costly late-stage failures in the clinic.

Soo Min Choi, Director, SCINCO: “Our dual-approach covering in-house development and the distribution of high-quality equipment from international manufacturers ensures we offer a comprehensive range of solutions to meet the diverse needs of all researchers, while leveraging unique insights to understand the scientific business landscape.” He added: “The global NAM market is growing at a rapid pace and to maintain the increased momentum across our industry, we believe adoption of these tools will become essential. We’re excited to be a part of the movement to bring CN Bio’s next-generation OOC solutions to the South Korean market.

Dr Paul Brooks, CEO, CN Bio: “Recent regulatory updates from the FDA are fueling a rapidly growing, global interest in human-relevant alternatives in drug development. Recognizing this, we are progressing an ambitious growth strategy to respond to market demand and put in place essential sales and support channels to ensure we remain ahead of the curve in addressing customers’ research needs. Partnering with SCINCO is an exciting development, allowing us to draw upon the team’s unique insights into the scientific and business landscape in South Korea to provide a strong footing as we expand further in the APAC region.”

1. https://cn-bio.com/important-fda-announcement/
2. Press release (13 January, 2025): CN-Bio Partners with Primetech to Distribute OOC Solutions

Cambridge, UK, 24 April 2025: CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix^® technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development.

The initial phase of the collaboration will focus on validating CN Bio’s PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies.

Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron’s facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges.

Dr Paul Brooks, CEO, CN Bio, said:

“Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before.

Dr Tomasz Kostrzewski, CSO, CN Bio, commented:

“The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.”

Dr Hua Yang, CSO, Pharmaron, added:

“We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners’ development programs.”

In the press release, the FDA cites their promotion of lab-grown human organoids, or organ-on-a-chip systems, to test drug safety because these models can reveal toxic effects that could remain undetected in animals, providing “a more direct window into human responses”

Read the press release to learn more about the key benefits of replacing animal testing in monoclonal antibody safety evaluation with human-based lab models and advanced computer simulations, including:

• The FDA’s roadmap for implementation
• Regulatory incentives to encourage investment in modernized testing platforms
• Long-term proposal (3-5 years) to make animal studies the exception rather than the norm by switching to a “NAM-based default” for pre-clinical safety/toxicology testing

“The recent announcement from the FDA is really a watershed moment for the biopharma industry, with a clear call to action for drug developers to move away from traditional animal safety testing and replace them with human-relevant methods such as organ-on-a-chip.

This change will really accelerate the adoption of organ-on-a-chip (OOC) and other new alternative human methods by drug developers, ultimately leading to faster drug development, reduced R&D costs and more cost-effective medicines for patients.

It is humbling to see the many years of hard work by the CN Bio team and our partners being recognised by the announcement and the roadmap laid out by the FDA leadership.” Dr Tomasz Kostrzewski. CSO, CN Bio

Visit our Immune-mediated liver injury application page for more information about how PhysioMimix_^® OOC assays support the safety profiling of mAbs and your response to the FDA’s roadmap.

Related News & Resouces

News & Blogs

CN Bio to participate in 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI

Scientific publications

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation

News & Blogs

Why the FDA animal testing phase-out for monoclonal antibodies?

News & Blogs

Microphysiological systems for mAbs development: how do they address animal limitations?

All-in-one DILI assay kit enables in-house, in vitro profiling of human drug-induced liver injury

• Rapid access to CN Bio’s FDA-recognized human DILI assay to optimize and de-risk drug candidate selection
• 24 replicates to support simultaneous assessment of up to eight conditions per kit

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix^® DILI assay kit: Human 24. Built upon CN Bio’s human-derived and highly characterized liver microphysiological system (MPS), the DILI assay kit provides robust, human-relevant insights into crucial drug safety parameters, to support more informed clinical progression of drug candidates, enhanced clinical preparedness, and help de-risk drug development workflows by ensuring only the most promising therapeutic candidates are selected.

Even today, 30% of drug candidates fail in clinical trials, and 18% of these failures are attributed to hepatotoxicity concerns¹. Existing methods to assess human drug-induced liver injury (DILI) use a combination of data sources, including in vitro assays, in vivo animal studies, and in silico modelling. Current preclinical approaches are limited by sensitivity, clinical translatability, and physiological relevance. CN Bio’s FDA-recognized liver MPS has been designed to overcome these limitations, providing robust, human-specific data to accurately inform drug-induced hepatotoxicity².

Initially launched as part of the Company’s contract research services (CRS)³, CN Bio’s human DILI assay has been further refined into an all-in-one kit to optimize preclinical drug development by providing deeper, physiologically relevant, mechanistic hepatotoxicity insights. The kit streamlines workflows by removing the challenges associated with MPS model development and validation, allowing new users to rapidly integrate the OOC solution into their own labs.

CN Bio’s liver model recreates highly functional and metabolically active hepatic tissues. It can be maintained under perfusion for up to two weeks and incorporates Kupffer cells to capture crucial aspects of the human innate immune system, facilitating deeper insights into the most complex toxicology events over extended timeframes. As the kit leverages primary human tissue, it also better supports the development of new, human-specific drug modalities, an area for which traditional preclinical tools often lack the relevant targets or pathways.

Every DILI assay kit provides 24 wells, allowing users to simultaneously assess up to eight conditions in triplicate. This breadth of data output, covering key DILI pathways, means that customers can easily screen a selection of drug candidates, supporting earlier identification of flawed molecules, improving efficiency and reducing cost.

Dr Ovidiu Novac, Senior Scientist and Project Manager (DILI assay kit), CN Bio, said:

“Toxicology testing is perhaps the most essential part of developing a new drug, but our current preclinical methods often fall short, putting therapeutic developers at risk of extremely costly, late-stage failures. Previously available via our CRS, we chose to further develop our DILI assay into a simple, all-in-one kit, in response to increasing demand for human-relevant, preclinical toxicology testing. With Human 24, PhysioMimix users can now more easily replicate our industry-leading DILI assay in their own lab, providing deeper mechanistic insights into drug-induced hepatoxicity and enabling more confident progression of drug candidates into the clinic.”

PhysioMimix^® DILI assay kit: Human 24

Learn more

References:

1. Walker PA, Ryder S, Lavado A, Dilworth Clive, Riley RJ. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol. 2020;94:2559-2585. doi:10.1007/s00204-020-02763-w
2. Rubiano A, Amruta Indapurkar |, Yokosawa R, et al. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci. 2021;14. doi:10.1111/cts.12969
3. Press Release (27 October 2020): Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech. In response to rapidly growing demand for the Company’s OOC solutions, the agreement establishes a new regional distribution network in Japan, providing customers streamlined access to localized support and technical expertise, and solidifies CN Bio’s presence in this key market.

Global legislative changes and localized drives have influenced the growing demand in Japan for new approach methodologies (NAMs). As a result, the country’s OOC market is expanding rapidly; predicted to reach a value of $28.2M by 2030 (CAGR 30.7%)¹. Pharmaceutical and biotech companies are recognizing the potential of these approaches to improve preclinical efficacy and safety data generation in drug discovery and development workflows, leading to reduced failure rates of new drug candidates. CN Bio has strategically partnered with Primetech Corp. to strengthen its presence in the Asia-Pacific region, expanding direct sales and product support for the Company’s range of industry-leading PhysioMimix^® OOC Systems and solutions to existing and new customers.

CN Bio’s benchtop PhysioMimix OOC range accurately mimics human physiology in the laboratory. Using advanced in vitro human organ models, these systems enable more accurate predictions of human drug responses to support the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models provide insights into crucial aspects of preclinical drug development, including drug bioavailability, toxicology and disease modelling, providing information on how drugs will perform in patients and reduce the risk of costly late-stage failures in the clinic.

Ryosuke Ogihara, CEO, Primetech Corporation: “We are pleased to announce the commencement of our partnership with CN Bio to offer the Company’s range of microphysiological systems and reagents. This innovative technology opens new possibilities in the field of drug discovery and development, and can significantly accelerate the discovery process. Our company is committed to providing cutting-edge solutions to drive our customers’ success, and we are confident that CN Bio’s products and expertise will greatly enhance their research efficiency.”

Dr Paul Brooks, CEO, CN Bio: “Partnering with an established distributor like Primetech marks a crucial milestone in our strategy for long-term global growth. Through this, we are solidifying our distribution network in Asia, allowing us to offer our ground-breaking OOC solutions in this region and meet rapidly growing market demand. This agreement will allow us to provide specialized local support to our Japanese customers, and underpins our ongoing commitment to being an international provider of gold-standard OOC solutions, revolutionizing drug discovery on a global scale.”

1. https://www.grandviewresearch.com/horizon/outlook/organ-on-a-chip-market/japan

• Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to accelerate and de-risk clinical progression of drug candidates
• Supports up to 18 data replicates and simulation of both intravenous and oral dosing routes

Cambridge, UK, 14 November 2024: CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix^® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.

Estimating bioavailability is an essential part of preclinical drug development and necessary to inform safe and effective dosage in the clinic. Currently, human drug bioavailability is estimated by combining several data sources, including in vitro assays, in vivo animal studies, and in silico modelling. Each of these have distinct drawbacks; with in vitro and 2D cell cultures unable to account for the complexity of drug absorption, and animal models having significant differences in physiology and metabolic capacity that limit data translatability into humans¹.

The kit has been developed following the successful launch of CN Bio’s PhysioMimix Bioavailability assay into its ADME Contract Research Service offerings in January 2024, in response to market demand for a novel approach to address the limitations of traditional methods. The Company has refined the assay into an easy-to-use kit format, enabling customers to rapidly onboard and recreate the assay in their own labs. The Bioavailability assay kit: Human 18 is optimized for use with the Company’s PhysioMimix^® Multi-organ System, uniquely bridging the gap between in vitro and in vivo studies to enable accurate and predictive profiling of human oral drug bioavailability earlier in the drug development process. It enables researchers to select and progress only the most promising therapeutic candidates, better inform in vivo study design, and minimize the number of animals required.

CN Bio’s Bioavailability assay harnesses the Company’s robust Gut/Liver-on-a-chip model (also known as a Gut/Liver microphysiological system), developed in partnership with Altis Biosystems. Leveraging the organ-specific expertise of each company, it fluidically links two human-derived and highly characterized models: Altis Biosystems’ RepliGut® Jejunum model and CN Bio’s FDA-recognized PhysioMimix Liver-on-a-chip, into one complete system. This dual-organ model accurately recapitulates key processes that determine bioavailability, including intestinal absorption, intestinal metabolism and hepatic clearance. Uniquely, it also enables users to simulate both intravenous and oral dosing routes, by assessing the models separately or as a combined system.

Dr Yassen Abbas, Lead Scientist, CN Bio:

“Human bioavailability is a crucial part of choosing which drug candidates to progress to the clinic, but an area that is notoriously poorly served by existing models. The PhysioMimix Bioavailability assay kit: Human 18 effectively tackles this issue, providing up to 18 replicates for our customers to profile their drug candidates in vitro, minimizing risk and maximizing the chance of clinical success. The kit modernizes workflows by removing the burden of assay development and validation, so researchers can rapidly onboard an OOC approach.”

Dr Ben Scruggs, CEO, Altis Biosystems:

“Recognizing the distinct market demand for new solutions to more accurately predict human bioavailability, we are pleased to be partnering with CN Bio to combine the benefits of our industry leading single-organ models into a perfused and metabolically capable Gut/Liver-on-a-chip model.” “The Bioavailability assay kit: Human 18 allows users to harness the model’s capabilities from their own labs for the first time, providing a streamlined route to access predictive human data through an easy-to-use in vitro model.”

Bioavailability assay kit: Human 18

Learn more

1. Musther, H. et al. (2014) ‘Animal versus human oral drug bioavailability: Do they correlate?’, European Journal of Pharmaceutical Sciences, 57, pp. 280–291

2. Press Release (23^rd January 2024): CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies